# NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma

> **NCT04215471** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Oesophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** PD-L1 Antibody SHR-1316

## Key facts

- **NCT ID:** NCT04215471
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04215471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04215471, "NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04215471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*